ADC Therapeutics (ADCT) Change in Accured Expenses (2019 - 2023)
Historic Change in Accured Expenses for ADC Therapeutics (ADCT) over the last 5 years, with Q4 2023 value amounting to $2.0 million.
- ADC Therapeutics' Change in Accured Expenses fell 8790.74% to $2.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$14.1 million, marking a year-over-year decrease of 22957.0%. This contributed to the annual value of $11.1 million for FY2024, which is 17876.69% up from last year.
- According to the latest figures from Q4 2023, ADC Therapeutics' Change in Accured Expenses is $2.0 million, which was down 8790.74% from -$519000.0 recorded in Q3 2023.
- In the past 5 years, ADC Therapeutics' Change in Accured Expenses ranged from a high of $16.2 million in Q4 2022 and a low of -$12.3 million during Q1 2023
- In the last 5 years, ADC Therapeutics' Change in Accured Expenses had a median value of $217.0 in 2019 and averaged -$268506.1.
- As far as peak fluctuations go, ADC Therapeutics' Change in Accured Expenses soared by 60560.75% in 2020, and later tumbled by 958464.91% in 2023.
- ADC Therapeutics' Change in Accured Expenses (Quarter) stood at $921.0 in 2019, then tumbled by 41.26% to $541.0 in 2020, then plummeted by 985682.26% to -$5.3 million in 2021, then soared by 404.6% to $16.2 million in 2022, then tumbled by 87.91% to $2.0 million in 2023.
- Its last three reported values are $2.0 million in Q4 2023, -$519000.0 for Q3 2023, and -$3.3 million during Q2 2023.